Overcoming <i>Mycobacterium tuberculosis</i> Drug Resistance: Novel Medications and Repositioning Strategies
Rohan Samir Kumar Sachan, Vyoma Mistry, Mayuri Dholaria, Abhishek Rana, Inderpal Devgon, Iftikhar Ali, Javed Iqbal, Sayed M. Eldin, Abdel Rahman Al-Tawaha, Saud Bawazeer, Joydeep Dutta, Arun Karnwal
Abstract
High Resolution Image Download MS PowerPoint Slide Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, is a global health concern, affecting millions worldwide. This bacterium has earned a reputation as a formidable adversary due to its multidrug-resistant nature, allowing it to withstand many antibiotics. The development of this drug resistance in Mycobacterium tuberculosis is attributed to innate and acquired mechanisms. In the past, rifampin was considered a potent medication for treating tuberculosis infections. However, the rapid development of resistance to this drug by the bacterium underscores the pressing need for new therapeutic agents. Fortunately, several other medications previously overlooked for tuberculosis treatment are already available in the market. Moreover, several innovative drugs are under clinical investigation, offering hope for more effective treatments. To enhance the effectiveness of these drugs, it is recommended that researchers concentrate on identifying unique target sites within the bacterium during the drug development process. This strategy could potentially circumvent the issues presented by Mycobacterium drug resistance. This review primarily focuses on the characteristics of novel drug resistance mechanisms in Mycobacterium tuberculosis . It also discusses potential medications being repositioned or sourced from novel origins. The ultimate objective of this review is to discover efficacious treatments for tuberculosis that can successfully tackle the hurdles posed by Mycobacterium drug resistance.